Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSW-1025 in Castration-resistant Prostate Cancer
NCT06441994Phase 1Active, not recruiting
- Sponsor
- The University of Osaka
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [211At]PSMA-5 in prostate cancer (PCa), sponsored by The University of Osaka. Primary endpoints: Treatment-related adverse events at 6 months and Dose Limiting Toxicity at 4 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
[211At]PSMA-5
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06441994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441994.